BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15802888)

  • 1. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B.
    Krüger WH; Kröger N; Rüssmann B; Renges H; Kabisch H; Zander AR
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S10-3. PubMed ID: 9916623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
    Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.
    Krüger W; Stockschläder M; Sobottka I; Betker R; De Wit M; Kröger N; Grimm J; Arland M; Fiedler W; Erttmann R; Zander AR
    Leuk Lymphoma; 1997 Feb; 24(5-6):491-9. PubMed ID: 9086439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
    Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
    Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation.
    Roman E; Osunkwo I; Militano O; Cooney E; van de Ven C; Cairo MS
    Pediatr Blood Cancer; 2008 Feb; 50(2):325-30. PubMed ID: 17514732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
    Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
    Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
    Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
    Bochennek K; Tramsen L; Schedler N; Becker M; Klingebiel T; Groll AH; Lehrnbecher T
    Clin Microbiol Infect; 2011 Dec; 17(12):1868-74. PubMed ID: 21895857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients].
    López-Medrano F; Díaz-Pedroche C; Lumbreras C; Aguado JM
    Rev Esp Quimioter; 2005 Mar; 18(1):14-20. PubMed ID: 15915227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.